From GlobeNewswire: 2025-06-17 09:30:00

The Biodefense Market was valued at USD 16.03 billion in 2023, projected to reach USD 25.06 billion by 2032. The US accounted for USD 9.69 billion in 2023. Market growth is fueled by bioterrorism threats, government investments, and innovative pathogen detection technologies.

Biodefense strategies, diagnostics, vaccines, and therapeutics protect against biological threats. Integration of biosensors, AI, and emergency stockpiling initiatives enhance global health security against anthrax, smallpox, botulinum, and synthetic biohazards.

Major players in the market include XOMA Corporation, Altimmune Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, SIGA Technologies, and more. These companies offer various biodefense vaccines and therapeutics.

North America dominated the biodefense market in 2023, with the US leading in policy-making, surveillance programs, and countermeasure development. Asia-Pacific is expected to witness rapid growth due to increased investments in bioterrorism countermeasures.

Recent developments include Acurx Pharmaceuticals’ progress against ciprofloxacin-resistant Anthrax, Aditxt Inc.’s acquisition of Appili Therapeutics, and Emergent BioSolutions’ funding for anthrax and smallpox vaccines. Rising global zoonotic diseases and lab-engineered pathogens emphasize the need for surveillance systems and vaccines.

Government spending accounts for over 70% of total biodefense expenditure globally. Detection and diagnostic devices for pathogens are projected to exceed 10 million units globally by 2032. Over 35 biodefense candidates, including vaccines and antitoxins, were in advanced development as of 2023.



Read more at GlobeNewswire: Biodefense Market to Reach USD 25.06 Billion by 2032,